Active Pharmaceutical Ingredient (API) Market Size - US$ 260 Bn by 2026 | CAGR 6.5%

Category : Healthcare and Pharmaceuticals | Delivery Format : PDF | Status: Published | Pages : 160

Introduction

The global Active Pharmaceutical Ingredient market is forecasted to grow at a stable CAGR around 6.5% during the forecast period 2018 to 2026 and reach the market value around USD 260 billion by 2026.

API is synthetically and organically dynamic parts of medications with direct impact in cure, moderation, treatment and counteractive action of maladies. The worldwide API market has seen enormous development in the course of the most recent couple of decades inferable from the expanded utilization of medications and biologics in the treatment of maladies. The expanding appropriation of value models in API manufacturing, for example, Good Manufacturing Practices (GMP), current GMP (cGMP), and the worldwide reception of International Conference on Harmonization (ICH) rules, has improved the security guidelines. On the other hand, the API business is confronting the difficulties, for example, shortening the improvement time, diminishing the expense of advancement, improving the procedure structure and fulfilling the quality guideline without settling on the benefit. The report provides analysis of global Active Pharmaceutical Ingredient (API) market for the period 2015-2026, wherein 2018 to 2026 is the estimate period and 2017 is considered as the base year.

Report coverage

Market Active Pharmaceutical Ingredient (API) Market
Analysis Period 2018 - 2026
Base Year 2017
Forecast Data 2019 - 2026
Segments Covered By Synthesis, By Manufacturer, By Type, By Application and By Geography
Regional Scope North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
Key Companies Profiled AbbVie Inc.; Merck & Co., Inc.; Boehringer Ingelheim International GmbH; Teva Pharmaceutical Industries Ltd; Cipla, Inc.; Albemarle Corporation; Bristol-Myers Squibb Company; Sun Pharmaceutical Industries Ltd.; Mylan N.V.; Aurobindo Pharma; and Dr. Reddy’s Laboratories Ltd.
Report Coverage
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis
Customization Scope 10 hrs of free customization and expert consultation


Market Dynamics

The global active pharmaceutical ingredients market is probably going to be impacted by an extensive number of innovative medications going off patent in the ongoing years. There is an approaching requirement for mechanical advancements to keep up the benefit in high volume and a low esteem condition. The central point driving the market development are, rising occurrences of oncology, cardiovascular, diabetes and lifestyle infections, rising number of clinics and indicative focuses, rising geriatric populace in emerging nations, expanding human services consumption, expanding illness responsiveness and instruction. On the other hand, an absence skilled gifted workforce and constrained availability of medications in the emerging nations are probably going to confine the market development.

Active Pharmaceutical Ingredient (API) Industry, by Type of Synthesis

  • Biotech
    • Monoclonal antibodies
    • Recombinant proteins
    • Vaccines
  • Synthetic

Active Pharmaceutical Ingredient (API) Market, by Type of Manufacturer

  • Captive APIs
  • Merchant APIs

Active Pharmaceutical Ingredient (API) Market, by Type

  • Innovative APIs
  • Generic APIs

Active Pharmaceutical Ingredient (API) Market, by Application

  • Cardiology
    • Generic
    • Innovative
  • Orthopedic
    • Generic
    • Innovative
  • Oncology
    • Generic
    • Innovative
  • Endocrinology
    • Generic
    • Innovative
  • Pulmonology
    • Generic
    • Innovative
  • Gastroenterology
    • Generic
    • Innovative
  • CNS & Neurology
    • Generic
    • Innovative
  • Nephrology
    • Generic
    • Innovative
  • Ophthalmology
    • Generic
    • Innovative
  • Others

Global Active Pharmaceutical Ingredient (API) Market, by Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Chile
    • Rest of Latin America
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • Rest of MEA

The market research study on “Active Pharmaceutical Ingredient (API) Market (By Type of Synthesis: Biotech [Monoclonal antibodies, Recombinant proteins, Vaccines], Synthetic; By Type of Manufacturer: Captive APIs, Merchant APIs; By Type: Innovative APIs, Generic APIs; By Application: Cardiology [Generic, Innovative], Orthopedic [Generic, Innovative], Oncology [Generic, Innovative], Endocrinology [Generic, Innovative], Pulmonology [Generic, Innovative], Gastroenterology [Generic, Innovative], CNS & Neurology[Generic, Innovative], Nephrology [Generic, Innovative], Ophthalmology [Generic, Innovative], Others) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2018 - 2026” offers detailed insights on global Active Pharmaceutical Ingredient (API) market segments with market dynamics and their impact. The report provides insights on global Active Pharmaceutical Ingredient (API) market by type of synthesis, type of manufacturer, type, application, and major geographic regions. The report also covers basic technology development policies.

Market Participants

The Active Pharmaceutical Ingredient (API) market is consolidated with large number of manufacturers. The company profiling of key players in the market includes major business strategies, company overview and revenues. The key players of the market are AbbVie Inc.; Merck & Co., Inc.; Boehringer Ingelheim International GmbH; Teva Pharmaceutical Industries Ltd; Cipla, Inc.; Albemarle Corporation; Bristol-Myers Squibb Company; Sun Pharmaceutical Industries Ltd.; Mylan N.V.; Aurobindo Pharma; and Dr. Reddy’s Laboratories Ltd.

Frequently Asked Questions

Active Pharmaceutical Ingredient Market is forecasted to grow at a CAGR of 6.5% over the forecast period 2019 to 2026.

The global active pharmaceutical ingredient market is expected to reach value around USD 260 bn by 2026.

API is synthetically and organically dynamic parts of medications with direct impact in cure, moderation, treatment and counteractive action of maladies.

The key players of the market are AbbVie Inc.; Merck & Co., Inc.; Boehringer Ingelheim International GmbH; Teva Pharmaceutical Industries Ltd; Cipla, Inc.; Albemarle Corporation; Bristol-Myers Squibb Company; Sun Pharmaceutical Industries Ltd.; Mylan N.V.; Aurobindo Pharma; and Dr. Reddy’s Laboratories Ltd.

The market in Asia Pacific is anticipated to extend at a fast pace amid the conjecture time frame.

North America is expected to hit largest revenue share in active pharmaceutical ingredient market?

In the coming years, the market is expected to gain pace as a result of recent advancements in the biopharmaceutical sector.

Cart Summary